Targeting dormant leukaemia cells
Nature
2008년5월12일
A new role for a protein involved in leukaemia is described in Nature this week; the research demonstrates its potential as a therapeutic target to eradicate dormant leukaemia-initiating cells.
The promyelocytic leukaemia protein (PML) tumour suppressor is known to be involved in the development of some forms of leukaemia. Pier Paolo Pandolfi and colleagues identify a new and unexpected role for PML in the maintenance of both haematopoietic stem cells and leukaemia-initiating cells. They demonstrate, in mice, that targeting the protein with arsenic trioxide eliminates the cancer-initiating cells, thought to be resistant to chemotherapy and other therapies.
The team believes that their results present a new pharmacological approach to target cells that are missed by other therapies and therefore lead to disease relapse.
doi: 10.1038/nature07016
리서치 하이라이트
-
7월29일
Engineering: Just add water to activate a disposable paper batteryScientific Reports
-
7월26일
Physics: Slab avalanche origin similar to that of earthquakesNature Physics
-
7월13일
Planetary science: Origins of one of the oldest martian meteorites identifiedNature Communications
-
7월12일
Astronomy: Casualty risk from uncontrolled rocket re-entries assessedNature Astronomy
-
7월12일
Physics: Beam vibrations used to measure ‘big G’Nature Physics
-
7월6일
Biotechnology: Mice cloned from freeze-dried somatic cellsNature Communications
